Table 1

Characteristics of included guidelines and consensus statements

Document	Issuing organisation	Year of publication	Country	Funding body	Target population	Target audience	Guideline development group	Guideline review	Guideline update	Evidence base	LOE	SOR
Guidelines
SAMA_200351	South African Medical Association	2003	South Africa	Pharmaceutical company	Gout	Phy	Multi	ER	Intermittent	NG	–	–
EULAR_200618	EULAR	2006	Europe	EULAR	Gout	NG	Rheu	NG	NG	SLR	+	+
MOH_MSR_AMM_200849	MOH, MSR, AMM	2008	Malaysia	Pharmaceutical company	Adults (>16 years) with gout	Phy	Multi	ER	2012 or sooner	SLR	+	+
PRA_200850	Philippine Rheumatology Association	2008	Philippine	NG	Gout	Phy	NG	NG	Three or more years	SLR	+	+
UTAustin_200952	University of Texas at Austin	2009	US	University of Texas at Austin	Adults with gout	Phy	NG	ER	NG	SLR	+	+
EULAR_201117	EULAR	2011	Multination	Pharmaceutical company, ASCR	Gout	Phy	Multi	NG	NG	SLR	+	+
JSGNAM_201148	Japanese Society of Gout and Nucleic Acid Metabolism	2011	Japan	NG	Hyperuricemia or gout	NG	NG	ER	NG	SLR	+	+
ACR_201214 15	ACR	2012	US	ACR, NIAMS, NIH	Gout	Phy	Multi	NG	Intermittent	SLR	+	–
SER_201346	Spanish Society of Rheumatology	2013	Spain	Pharmaceutical company	Gout	Phy	Multi	ER	Four years	SLR	+	+
SIR_201345	Italian Society of Rheumatology	2013	Italy	NG	Gout	Phy	Multi	NG	NG	SLR	+	+
FMOH_201444	Federal Ministry of Health (Nigeria)	2014	Nigeria	NG	Gout	Phy, Pts in Nigeria	Multi	NG	NG	NG	–	–
CRA_201641	Chinese Rheumatology Association	2016	China	NG	Gout in China	Phy	Multi	NG	NG	SLR	+	+
EULAR_201616	EULAR	2016	Europe	NG	Gout	Phy, Pts	Multi	ER	Intermittent	SLR	+	+
TRA_201638	Taiwan Rheumatology Association	2016	Taiwan, China	NG	Hyperuricemia or gout	Phy, Pts	Multi	NG	NG	NG	–	–
ACP_2017 19 20	ACP	2017	US	ACP	Acute and recurrent gout	Phy	NG	ER	Five years	SLR	+	+
BSR_201721	The British Society for Rheumatology	2017	UK	No specific funding	Gout in the UK	Phy	Multi	ER	Planned in 2020	SLR	+	+
Consensus statements
CCCP_201247	Chinese College of Cardiovascular Physicians	2012	China	NG	Asymptomatic hyperuricemia with CVD	NG	NG	NG	NG	CS	–	–
3e_201336	3e Initiative	2013	Multination	Pharmaceutical company	Gout	NG	Rheu	NG	NG	SLR	+	+
CSE_201 3 37	Chinese Society of Endocrinology	2013	China	NG	Hyperuricemia or gout	NG	NG	NG	NG	CS	–	–
3e_PT_201440	Portuguese 3e Initiative	2014	Portugal	NG	Gout in Portuguese	NG	Rheu	NG	NG	SLR	+	+
3e_AU_NZ_201543	Australian and New Zealand 3e Initiative	2015	Multination	NG	Gout	NG	Rheu	NG	NG	SLR	+	+
ACR_EULAR_201542	ACR/EULAR	2015	Multination	ACR, EULAR	Gout	NG	NG	ER	Intermittent	SLR	–	–
T2T_201639	NG	2016	Multination	Pharmaceutical company	Gout	NG	Rheu	ER	NG	SLR	+	+
CRA_multi_201722	Chinese multidisciplinary expert task force on hyperuricemia and its related diseases	2017	China	NG	Hyperuricemia	Phy	Multi	NG	NG	CS	–	–

ACP, American College of Physicians; ACR, American College of Rheumatology; AMM, Academy of Medicine of Malaysia; ASCR, American Society of Clinical Rheumatologists; CS, consensus statement; CVD, cardiovascular diseases; ER, external review; EULAR, European League Against Rheumatism; LOE, level of evidence; MOH, Ministry of Health Malaysia; MSR, Malaysian Society of Rheumatology; Multi, multidisciplinary development group; NG, not given; NIAMS, National Institute of Arthritis and Musculoskeletal and Skin Diseases; NIH, National Institutes of Health; Phy, physicians; Pt, patients; Rheu, rheumatologists; SLR, systematic literature review; SOR, strength of recommendation; 3e, evidence, expertise, exchange.